Researchers Developed AI Tools to Identify Dementia Risk
New AI-based screening tools designed to spot early dementia markers are currently undergoing clinical evaluation.
Updated on Sept. 20, 2026 in Alzheimer’s
Live Poll
Do you trust artificial intelligence to assist doctors in diagnosing early-stage medical conditions?
In early 2026, researchers completed the first phase of the AI-Mind project, which created two new digital tools to identify dementia risk. The project, which was funded by the European Union, analyzed 50,000 hours of data to improve early detection and monitoring capabilities.
Why it matters
Identifying patients before clinical symptoms fully manifest may provide more opportunities for monitoring and intervention. This approach aims to extend the amount of time individuals live without significant symptoms.
The AI-Mind project analyzed 50,000 hours of data from 1,000 European participants to develop risk-assessment tools. The effectiveness of these tools in diverse clinical settings is currently being tested following the completion of the project's first phase.
The players
Eli Lilly
A pharmaceutical company researching therapies for neurodegenerative conditions including Alzheimer's disease.
Roche
A healthcare company focused on diagnostics and pharmaceuticals, including specialized testing for Alzheimer's.
Bosch
A global engineering and technology company that provides expertise in sensor data and connected systems.
The details
The AI-Mind Connector identifies specific patterns in brain electrical activity that correlate with dementia risk. Separately, the AI-Mind Predictor analyzes a combination of cognitive function, biological markers, medical history, and demographic data to assess the likelihood of progression from mild cognitive impairment to dementia.
Timeline
The first phase of the AI-Mind project concluded in early 2026.
Clinical evaluation for EU Medical Device Regulation approval is expected to be completed by 2035.
Health Landscape
The AI-Mind project represents a broader trend of integrating artificial intelligence into neurological screening protocols. This research follows the established pattern of leveraging large-scale data collection to identify early biomarkers for neurodegenerative decline.
These tools are currently in testing and not yet available for clinical use, so they do not change your current care plan. If you or a family member have concerns about memory changes, discuss your symptoms with a primary care physician to explore current diagnostic options.
The takeaway
Early identification is a major focus in dementia research, with 7 percent of Europeans over 60 currently affected. Tracking changes in cognitive function or unusual memory lapses remains the most important step for patients to discuss with their doctors today.
Further reading
For more on the current methods used to monitor and detect cognitive decline, visit Alzheimer’s.
Source note: This article includes information reported by Cyprus Mail.
Live Poll
Do you trust artificial intelligence to assist doctors in diagnosing early-stage medical conditions?
